National Health Investors (NYSE:NHI) Price Target Raised to $86.00

Key Points

• Wells Fargo raised its price target on National Health Investors (NHI) from $85.00 to $86.00 while keeping an "equal weight" rating, and the stock's consensus analyst target is about $86.83 with an average rating of "Moderate Buy."
• NHI reported Q results showing EPS of $1.22 (a $0.01 miss) but revenue of $105.82M (beating estimates and up 6.8% year‑over‑year), and it set FY 2026 guidance of $4.94–$4.99 in EPS—above the street's average forecast of $4.41.
• Institutional investors own about 62.51% of the stock, with major holders like Vanguard, State Street and JPMorgan having recently increased their positions.

National Health Investors (NYSE:NHI - Get Free Report) had its target price upped by investment analysts at Wells Fargo & Company from $85.00 to $86.00 in a report released on Friday,Benzinga reports. The firm currently has an "equal weight" rating on the real estate investment trust's stock. Wells Fargo & Company's price objective would suggest a potential upside of 3.81% from the company's previous close.

Other equities research analysts have also issued research reports about the company. Cantor Fitzgerald set a $85.00 price target on National Health Investors in a research note on Monday, January 5th. National Bank Financial set a $85.00 price objective on National Health Investors in a research report on Tuesday, January 20th. Weiss Ratings reissued a "buy (b)" rating on shares of National Health Investors in a report on Monday, December 29th. Truist Financial boosted their target price on National Health Investors from $85.00 to $92.00 and gave the stock a "buy" rating in a research report on Thursday, March 12th. Finally, KeyCorp upped their target price on National Health Investors from $80.00 to $88.00 and gave the stock an "overweight" rating in a research note on Thursday, December 4th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $86.83.

National Health Investors Price Performance

Shares of NYSE:NHI opened at $82.84 on Friday. The company's fifty day moving average price is $84.50 and its 200-day moving average price is $79.76. The company has a debt-to-equity ratio of 0.76, a current ratio of 6.90 and a quick ratio of 6.90. The firm has a market capitalization of $4.01 billion, a price-to-earnings ratio of 27.43, a PEG ratio of 4.50 and a beta of 0.65. National Health Investors has a one year low of $66.41 and a one year high of $91.38.

National Health Investors (NYSE:NHI - Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The real estate investment trust reported $1.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.23 by ($0.01). National Health Investors had a return on equity of 9.56% and a net margin of 37.81%.The company had revenue of $105.82 million for the quarter, compared to the consensus estimate of $95.12 million. During the same period in the prior year, the firm posted $1.24 earnings per share. The business's revenue was up 6.8% on a year-over-year basis. National Health Investors has set its FY 2026 guidance at 4.940-4.990 EPS. On average, equities research analysts anticipate that National Health Investors will post 4.41 earnings per share for the current fiscal year.

Hedge Funds Weigh In On National Health Investors

A number of large investors have recently bought and sold shares of NHI. Vanguard Group Inc. boosted its stake in shares of National Health Investors by 0.8% during the third quarter. Vanguard Group Inc. now owns 6,498,414 shares of the real estate investment trust's stock valued at $516,624,000 after purchasing an additional 52,474 shares during the period. State Street Corp raised its holdings in National Health Investors by 5.0% during the 2nd quarter. State Street Corp now owns 2,023,381 shares of the real estate investment trust's stock valued at $143,651,000 after buying an additional 95,812 shares during the last quarter. Principal Financial Group Inc. raised its holdings in National Health Investors by 1.9% during the 4th quarter. Principal Financial Group Inc. now owns 1,668,006 shares of the real estate investment trust's stock valued at $127,386,000 after buying an additional 30,968 shares during the last quarter. JPMorgan Chase & Co. boosted its position in National Health Investors by 34.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,613,051 shares of the real estate investment trust's stock valued at $128,238,000 after buying an additional 409,559 shares during the period. Finally, Geode Capital Management LLC boosted its position in National Health Investors by 1.5% during the 4th quarter. Geode Capital Management LLC now owns 1,262,657 shares of the real estate investment trust's stock valued at $96,443,000 after buying an additional 18,198 shares during the period. 62.51% of the stock is owned by hedge funds and other institutional investors.

About National Health Investors

National Health Investors, Inc NYSE: NHI is a specialized real estate investment trust (REIT) focused on owning and financing high-quality healthcare and senior housing facilities in the United States. The company's portfolio encompasses a diverse range of properties, including skilled nursing centers, assisted living and memory care communities, behavioral health facilities, dialysis clinics, and medical office buildings. NHI typically enters into long-term net-lease agreements with experienced healthcare operators, providing stable and predictable rental income streams while enabling its tenants to concentrate on delivering quality care.

Since its founding in 1991 and initial public offering later that year, National Health Investors has pursued a disciplined growth strategy centered on strategic acquisitions, joint ventures, and selective development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.